<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03629925</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308C303</org_study_id>
    <nct_id>NCT03629925</nct_id>
  </id_info>
  <brief_title>Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC</brief_title>
  <official_title>A Randomized, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Sintilimab (IBI308) in Combination With Gemcitabine and Platinum-Based Chemotherapy vs. Placebo in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Treatment for Patients With Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer (NSCLC) (ORIENT-12)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety Evaluation of IBI308 in Patients with Advanced or Recurrent Squamous&#xD;
      NSCLC&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The anti-tumor activity of anti-PD-1 therapy in previously untreated Chinese squamous NSCLC&#xD;
      patients will be investigated in this clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">October 15, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS(Progression Free Survival)</measure>
    <time_frame>Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)</time_frame>
    <description>PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS according to RECIST 1.1 as assessed by BIRRC was reported for each arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS (Overall Survival)</measure>
    <time_frame>Through Database Cutoff Date of 15 October 2019 (up to approximately 13 months)</time_frame>
    <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. OS was reported for each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR(Objective Response Rate)</measure>
    <time_frame>Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)</time_frame>
    <description>ORR was defined as the percentage of participants in the analysis population who had a confirmed Complete Response (CR: disappearance of all lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1. The percentage of participants who experienced a confirmed CR or PR according to RECIST 1.1 as assessed by BIRRC was reported as the ORR for each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR (Time to Response)</measure>
    <time_frame>Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)</time_frame>
    <description>TTR was defined as the time of participants from the first treatment administration to the first incidence of a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1. The time from first treatment administration to the first incidence of treatment response was reported as the TTR for each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR (Disease Control Rate)</measure>
    <time_frame>Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)</time_frame>
    <description>DCR was defined as the percentage of participants who had a CR (disappearance of all target lesions), PR (at least a 30% decrease in the sum of diameters of target lesions), or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD]). The percentage of participants who experienced a confirmed CR, PR, or SD according to RECIST 1.1 as assessed by BIRRC was reported as the DCR for each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR (Duration of Response)</measure>
    <time_frame>Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)</time_frame>
    <description>For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BIRRC assessment. The DOR according to RECIST 1.1 for all participants who experienced a confirmed CR or PR was reported for each arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">357</enrollment>
  <condition>Squamous NSCLC</condition>
  <arm_group>
    <arm_group_label>Sintilimab+ gemcitabine plus platinum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sintilimab combination arm: Sintilimab in combination with gemcitabine plus cisplatin or carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+gemcitabine plus platinum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo combination arm: Placebo in combination with gemcitabine plus cisplatin or carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>200mg, Q3W, day1, I.V.; consecutive cycles</description>
    <arm_group_label>Sintilimab+ gemcitabine plus platinum</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000mg/m^2, Q3W, day 1and 8, I.V.; first 4 or 6 consecutive cycles.</description>
    <arm_group_label>Placebo+gemcitabine plus platinum</arm_group_label>
    <arm_group_label>Sintilimab+ gemcitabine plus platinum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m^2, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.</description>
    <arm_group_label>Placebo+gemcitabine plus platinum</arm_group_label>
    <arm_group_label>Sintilimab+ gemcitabine plus platinum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>NA, Q3W, day1, I.V.; consecutive cycles</description>
    <arm_group_label>Placebo+gemcitabine plus platinum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 5mg/ml/min, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.</description>
    <arm_group_label>Placebo+gemcitabine plus platinum</arm_group_label>
    <arm_group_label>Sintilimab+ gemcitabine plus platinum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants must sign written ICF prior tothe implementation of any procedures&#xD;
             related to the study;&#xD;
&#xD;
          2. Aged ≥ 18 years and ≤ 75 years;&#xD;
&#xD;
          3. With a life expectancy of more than 3 months;&#xD;
&#xD;
          4. With at least one measurable lesion confirmed by the investigator according to RECIST&#xD;
             v1.1.&#xD;
&#xD;
             Measurable lesions locatedin the field of previous radiotherapy or locoregional&#xD;
             therapy canbe selected as target lesions if PD is confirmed;&#xD;
&#xD;
          5. Participants with histologically or cytologically confirmed locally advanced (stage&#xD;
             IIIB/IIIC) who are ineligible for radical surgery or concurrent chemoradiotherapy,&#xD;
             metastatic (stage IV)or recurrent squamous NSCLC based on the &quot;8th Edition of the TNM&#xD;
             Classification for LungCancer&quot; issued by the International Association for the Study&#xD;
             of Lung Cancer and the American Joint Committee on Cancer Classification;&#xD;
&#xD;
          6. With an ECOG PS score of 0 or 1;&#xD;
&#xD;
          7. Have not received any prior systemic anti-tumor therapy for advanced/metastatic&#xD;
             disease; for participants who have received prior platinum-based adjuvant&#xD;
             chemotherapy/radiotherapy,neoadjuvant chemotherapy/radiotherapy, or radical&#xD;
             chemoradiotherapy, they are eligible for the study if PD occurs at &gt; 6 months after&#xD;
             the last treatment;&#xD;
&#xD;
          8. With adequate hematologic function, defined as ANC ≥ 1.5 × 10^9/L, platelet count ≥&#xD;
             100 × 10^9/L, and hemoglobin ≥ 90 g/L (noblood transfusion history within 7 days);&#xD;
&#xD;
          9. Adequate hepatic function, defined as TBIL ≤ 1.5 × ULN and AST as well as ALT ≤ 2.5 ×&#xD;
             ULN for all participants, or AST and ALT ≤ 5 × ULN for participants with liver&#xD;
             metastasis;&#xD;
&#xD;
         10. Adequate renal function, defined as CCr ≥ 50 mL/min (Cockcroft-Gault formula);&#xD;
&#xD;
         11. Adequate coagulation function, defined as INR or PT ≤ 1.5 × ULN; for the participant&#xD;
             who is receiving anticoagulant therapy, INR or PT within the proposed scope of the&#xD;
             anticoagulantmedication is acceptable;&#xD;
&#xD;
         12. Female participants of childbearing age should be tested negative for urine or serum&#xD;
             pregnancy within 3 days before the first dose of the study treatments. A blood&#xD;
             pregnancy testis required if the urine pregnancy test is inconclusive;&#xD;
&#xD;
         13. For male and female participants with conception potential, highly effective&#xD;
             contraception measures (failure rate &lt; 1% per year) should be taken until at least 180&#xD;
             days afterdiscontinuation of the study treatment;&#xD;
&#xD;
        Note: Abstinence is acceptable as a method of contraception if it is the usual lifestyle&#xD;
        and preferred method of contraception for the participant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histological type of nonsquamousNSCLC. The dominant cell morphology must be identified&#xD;
             for mixed cell type (participants with squamous cell carcinoma components &gt; 50% can&#xD;
             beenrolled); participants with small cell carcinoma, neuroendocrine carcinoma, and&#xD;
             sarcoma components cannot be included;&#xD;
&#xD;
          2. Participants with known EGFR-sensitive mutations or ALK rearrangement;&#xD;
&#xD;
          3. Currently participating in an interventional clinical study, or treated with another&#xD;
             study drug therapy or investigational device therapy within 4 weeks before the first&#xD;
             dose;&#xD;
&#xD;
          4. Previously received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2&#xD;
             agents or agents targeting another stimulation or synergistically inhibiting TCR&#xD;
             (e.g., CTLA-4, OX-40,and CD137);&#xD;
&#xD;
          5. Received proprietary Chinese medicines with anti-tumor indications or immunomodulators&#xD;
             (thymosin, interferon, interleukin, etc.) within 2 weeks prior to the first dose, or&#xD;
             received a major surgery within 3 weeks prior to the first dose;&#xD;
&#xD;
          6. With active hemoptysis, active diverticulitis, abdominal abscess, gastrointestinal&#xD;
             obstruction, and peritoneal metastases requiring clinical intervention;&#xD;
&#xD;
          7. Have undergone solid organ transplantation or hematologic transplantation;&#xD;
&#xD;
          8. With clinically uncontrolled pleural effusion/ascites (participants who do not need&#xD;
             effusion drainage or have no significant increase in effusion within 3 days after&#xD;
             stopping drainage canbe enrolled);&#xD;
&#xD;
          9. With a tumor compressing the surrounding important organs (such as esophagus) with&#xD;
             relevant symptoms, compressing the superior vena cava, or invading the mediastinal&#xD;
             great vessels,heart, etc.;&#xD;
&#xD;
         10. With Class III-IV congestive cardiac failure (based on New York Heart Association&#xD;
             Classification) or poorly controlled and clinically significant arrhythmia;&#xD;
&#xD;
         11. With any arterial thrombosis, embolism, or ischemia within 6 months prior to&#xD;
             enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident,&#xD;
             and transient ischemicattack. With a history of deep venous thrombosis, pulmonary&#xD;
             embolism, or any other seriousthromboembolic events within 3 months priorto enrollment&#xD;
             (implantable port or catheter-related thrombosis, or superficial venous thrombosis is&#xD;
             not considered as &quot;serious&quot;thromboembolism);&#xD;
&#xD;
         12. With known allergy to the active ingredients and/or any excipient of sintilimab ,&#xD;
             gemcitabine, cisplatin, orcarboplatin;&#xD;
&#xD;
         13. With active autoimmune disease requiring systemic treatment (e.g., use of&#xD;
             disease-modifying drugs, corticosteroids, or immunosuppressive agents) within 2 years&#xD;
             before the first dose.Replacement therapy (e.g., thyroxine, insulin, or physiologic&#xD;
             doses of corticosteroids foradrenal or pituitary insufficiency) is not considered&#xD;
             systemic;&#xD;
&#xD;
         14. Participants requiring long-term systemic use of corticosteroids. Participants&#xD;
             requiring intermittent use of bronchodilators, inhaled corticosteroids, or&#xD;
             localinjection ofcorticosteroids for COPD or asthma can be included in the study;&#xD;
&#xD;
         15. Full recovery (i.e., ≤ Grade 1 or reaching the baseline, excluding asthenia or&#xD;
             alopecia) from toxicity and/or complications caused by any intervention has not&#xD;
             achieved before thestart oftreatment;&#xD;
&#xD;
         16. Diagnosed with other malignant tumors within 5 years before the first dose, excluding&#xD;
             radically cured cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma,&#xD;
             and/orradically resected carcinoma in situ. For other malignant tumors or lung cancer&#xD;
             diagnosedmore than 5 years before the first dose, pathological or cytological&#xD;
             diagnosis should beperformed for recurrent and metastatic lesions;&#xD;
&#xD;
         17. Symptomatic CNS metastasis. Participants with asymptomatic brain metastases or with&#xD;
             stable symptoms after treatment of brain metastases are allowed to participate in this&#xD;
             study as longas meeting all of the following criteria: presence of measurable lesions&#xD;
             outside the CNS;absence of metastases in midbrain, pons, cerebellum, meninges, medulla&#xD;
             oblongata, or spinalcord; maintain clinical stable condition for at least 2 weeks;&#xD;
             discontinue hormone therapy 14 days prior to the first dose of the study treatments;&#xD;
&#xD;
         18. With a history of non-infectious pneumonia requiring corticosteroid therapy within&#xD;
             1year prior to the first dose or with non-infectious pneumonia at present;&#xD;
&#xD;
         19. With an active infection requiring treatment or have used systemic anti-infective&#xD;
             drugs within one week prior to the first dose;&#xD;
&#xD;
         20. With known psychiatric disorder or substance abuse that could affect the compliance&#xD;
             with study requirements;&#xD;
&#xD;
         21. Known history of HIV infection (i.e. HIV 1/2 antibody positive), known syphilis&#xD;
             infection (syphilis antibody positive), or active tuberculosis;&#xD;
&#xD;
         22. With untreated active hepatitis B;&#xD;
&#xD;
             Note: Participants with hepatitis B who meet the following criteria are also eligible&#xD;
             forinclusion:&#xD;
&#xD;
             HBV viral load must be less than 1000 copies/mL (200 IU/mL) or below LLD prior to&#xD;
             thefirst dose, and participants should receive anti-HBV treatment to avoid virus&#xD;
             reactivation throughout the therapeutic phase of the study; For participants with&#xD;
             HBcAb (+), HBsAg (-), HBsAb (-), and HBV load (-), close monitoring is required&#xD;
             instead of prophylactic anti-HBV treatment to avoid virus reactivation;&#xD;
&#xD;
         23. Participants with active HCV infection (HCV antibody positive and HCV-RNA level above&#xD;
             the LLD);&#xD;
&#xD;
         24. Have received live vaccines within 30 days prior to the first dose; Note: Seasonal&#xD;
             inactivated influenza virus vaccines for injection are allowed, while liveattenuated&#xD;
             influenza vaccines forintranasal use are not acceptable;&#xD;
&#xD;
         25. With any medical history, disease, treatment, or laboratory abnormal finding that&#xD;
             would interfere with the study results or prevent the participant from participating&#xD;
             in the whole study,or the investigator believes that participation in this study is&#xD;
             not in the best interest of theparticipant;&#xD;
&#xD;
         26. With local or systemic diseases not attributing to malignancy, or with cancer-related&#xD;
             secondary diseases, which would result in a high medical risk and/or uncertainty in&#xD;
             survivalevaluation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caicun Zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital, Shanghai, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <results_first_submitted>January 18, 2021</results_first_submitted>
  <results_first_submitted_qc>March 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 1, 2021</results_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03629925/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03629925/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>primary analysis data cutoff date: 15 October 2019; updated analysis data cutoff date: 25 March 2020</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sintilimab+ Gemcitabine Plus Platinum</title>
          <description>Sintilimab 200mg IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
        </group>
        <group group_id="P2">
          <title>Placebo+Gemcitabine Plus Platinum</title>
          <description>Placebo IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sintilimab+ Gemcitabine Plus Platinum</title>
          <description>Sintilimab 200mg IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
        </group>
        <group group_id="B2">
          <title>Placebo+Gemcitabine Plus Platinum</title>
          <description>Placebo IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="179"/>
            <count group_id="B2" value="178"/>
            <count group_id="B3" value="357"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="7.47"/>
                    <measurement group_id="B2" value="61.0" spread="7.85"/>
                    <measurement group_id="B3" value="61.5" spread="7.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="357"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="357"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PFS(Progression Free Survival)</title>
        <description>PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS according to RECIST 1.1 as assessed by BIRRC was reported for each arm.</description>
        <time_frame>Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sintilimab+ Gemcitabine Plus Platinum</title>
            <description>Sintilimab 200mg IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+Gemcitabine Plus Platinum</title>
            <description>Placebo IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS(Progression Free Survival)</title>
          <description>PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS according to RECIST 1.1 as assessed by BIRRC was reported for each arm.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.9" upper_limit="6.8"/>
                    <measurement group_id="O2" value="4.9" lower_limit="4.8" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS (Overall Survival)</title>
        <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. OS was reported for each arm.</description>
        <time_frame>Through Database Cutoff Date of 15 October 2019 (up to approximately 13 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sintilimab+ Gemcitabine Plus Platinum</title>
            <description>Sintilimab 200mg IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+Gemcitabine Plus Platinum</title>
            <description>Placebo IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>OS (Overall Survival)</title>
          <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. OS was reported for each arm.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median OS and upper and lower limit of 95%CI not reached due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median OS and upper and lower limit of 95%CI not reached due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ORR(Objective Response Rate)</title>
        <description>ORR was defined as the percentage of participants in the analysis population who had a confirmed Complete Response (CR: disappearance of all lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1. The percentage of participants who experienced a confirmed CR or PR according to RECIST 1.1 as assessed by BIRRC was reported as the ORR for each arm.</description>
        <time_frame>Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sintilimab+ Gemcitabine Plus Platinum</title>
            <description>Sintilimab 200mg IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+Gemcitabine Plus Platinum</title>
            <description>Placebo IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>ORR(Objective Response Rate)</title>
          <description>ORR was defined as the percentage of participants in the analysis population who had a confirmed Complete Response (CR: disappearance of all lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1. The percentage of participants who experienced a confirmed CR or PR according to RECIST 1.1 as assessed by BIRRC was reported as the ORR for each arm.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" lower_limit="37.27" upper_limit="52.29"/>
                    <measurement group_id="O2" value="35.4" lower_limit="28.38" upper_limit="42.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TTR (Time to Response)</title>
        <description>TTR was defined as the time of participants from the first treatment administration to the first incidence of a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1. The time from first treatment administration to the first incidence of treatment response was reported as the TTR for each arm.</description>
        <time_frame>Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sintilimab+ Gemcitabine Plus Platinum</title>
            <description>Sintilimab 200mg IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+Gemcitabine Plus Platinum</title>
            <description>Placebo IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>TTR (Time to Response)</title>
          <description>TTR was defined as the time of participants from the first treatment administration to the first incidence of a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1. The time from first treatment administration to the first incidence of treatment response was reported as the TTR for each arm.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" lower_limit="1.2" upper_limit="11.1"/>
                    <measurement group_id="O2" value="1.41" lower_limit="1.2" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DCR (Disease Control Rate)</title>
        <description>DCR was defined as the percentage of participants who had a CR (disappearance of all target lesions), PR (at least a 30% decrease in the sum of diameters of target lesions), or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD]). The percentage of participants who experienced a confirmed CR, PR, or SD according to RECIST 1.1 as assessed by BIRRC was reported as the DCR for each arm.</description>
        <time_frame>Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sintilimab+ Gemcitabine Plus Platinum</title>
            <description>Sintilimab 200mg IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+Gemcitabine Plus Platinum</title>
            <description>Placebo IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>DCR (Disease Control Rate)</title>
          <description>DCR was defined as the percentage of participants who had a CR (disappearance of all target lesions), PR (at least a 30% decrease in the sum of diameters of target lesions), or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD]). The percentage of participants who experienced a confirmed CR, PR, or SD according to RECIST 1.1 as assessed by BIRRC was reported as the DCR for each arm.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0" lower_limit="80.08" upper_limit="90.75"/>
                    <measurement group_id="O2" value="80.3" lower_limit="73.73" upper_limit="85.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DOR (Duration of Response)</title>
        <description>For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BIRRC assessment. The DOR according to RECIST 1.1 for all participants who experienced a confirmed CR or PR was reported for each arm.</description>
        <time_frame>Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sintilimab+ Gemcitabine Plus Platinum</title>
            <description>Sintilimab 200mg IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+Gemcitabine Plus Platinum</title>
            <description>Placebo IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>DOR (Duration of Response)</title>
          <description>For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BIRRC assessment. The DOR according to RECIST 1.1 for all participants who experienced a confirmed CR or PR was reported for each arm.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" lower_limit="4.73" upper_limit="9.63"/>
                    <measurement group_id="O2" value="5.06" lower_limit="3.71" upper_limit="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through database cutoff date of 25 March 2020 (up to approximately 18 months)</time_frame>
      <desc>All adverse events, including serious adverse events, will be collected since the consent form is signed until 90th day after last administration of investigation products, either observed by investigator or by the spontaneous reported by subjects.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sintilimab+ Gemcitabine Plus Platinum</title>
          <description>Sintilimab 200mg IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
        </group>
        <group group_id="E2">
          <title>Placebo+Gemcitabine Plus Platinum</title>
          <description>Placebo IV, Gemcitabine 1.0 g/m^2 IV and Cisplatin 75 mg/m^2 or Carboplatin AUC 5 mg/ml/min IV Q3W.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Immune-mediated endocrinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Immune-mediated enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foreign body in gastrointestinal tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Immune-mediated pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bronchostenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>YiBo</name_or_title>
      <organization>Innovent Biologics (Suzhou) Co., Ltd</organization>
      <phone>+86 13382419112</phone>
      <email>jessica.yi@innoventbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

